Calliditas Therapeutics AB (Calliditas Therapeutics AB) Total Liabilities : $148.62 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Total Liabilities?

Calliditas Therapeutics AB's Total Liabilities for the quarter that ended in Dec. 2023 was $148.62 Mil.

Calliditas Therapeutics AB's quarterly Total Liabilities increased from Jun. 2023 ($111.87 Mil) to Sep. 2023 ($113.62 Mil) and increased from Sep. 2023 ($113.62 Mil) to Dec. 2023 ($148.62 Mil).

Calliditas Therapeutics AB's annual Total Liabilities increased from Dec. 2021 ($49.69 Mil) to Dec. 2022 ($114.35 Mil) and increased from Dec. 2022 ($114.35 Mil) to Dec. 2023 ($148.62 Mil).

Calliditas Therapeutics AB Total Liabilities Historical Data

The historical data trend for Calliditas Therapeutics AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Total Liabilities Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

6.06

24.82

49.69

114.35

148.62

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															72.61	114.35	111.87	113.62	148.62

Calliditas Therapeutics AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Calliditas Therapeutics AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	39.692	+	(94.232	+	10.289
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	4.06	+	0.343)
	=	148.62

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	181.255	-	32.64
	=	148.62

Calliditas Therapeutics AB's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	39.692	+	(94.232	+	10.289
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	4.06	+	0.343)
	=	148.62

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	181.255	-	32.64
	=	148.62

Calliditas Therapeutics AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.